Mankind Pharma Limited (NSE: MANKIND, BSE: 543904) – Board Approval of Strategic Investment and Majority Stake Acquisition in Armed Cell Therapeutics

Date of Announcement: 15 October 2026

---

Introduction

Mankind Pharma Limited (listed on NSE as MANKIND and BSE as 543904) disclosed the outcomes of its Board of Directors meeting held on 15 Oct 2026. The Board approved a substantial additional investment in its Dutch subsidiary and the acquisition of a controlling interest in a European biotechnology firm developing next‑generation CAR‑T cancer therapies.

---

Board Decision Summary

Item	Decision
Additional investment	Up to EUR 45 million in Mankind Pharma (Netherlands) B.V., raising the total authorized investment to EUR 50 million (including the previously approved EUR 5 million).
Acquisition	Purchase of 70 % of Armed Cell Therapeutics B.V. (ACTx) through Mankind Netherlands, funded with EUR 48 million in cash, to be paid in instalments.
Meeting timings	Commenced at 18:00 IST and concluded at 19:00 IST.

---

Investment Details

• Target vehicle: Mankind Pharma (Netherlands) B.V. (wholly‑owned subsidiary, incorporated 13 Aug 2026; authorized share capital EUR 50 mn, paid‑up EUR 0.02 mn, turnover nil).
• Purpose of additional capital: To finance the EUR 48 mn cash consideration for the 70 % stake in ACTx.
• Nature of transaction:
  • The capital infusion into Mankind Netherlands is a related‑party transaction (exempt under Regulation 23(5) of the SEBI Listing Regulations).
  • The subsequent investment from Mankind Netherlands into ACTx is not a related‑party transaction.

---

Acquisition of Armed Cell Therapeutics (ACTx)

• Company profile: Belgium‑incorporated biotechnology firm focused on next‑generation armed CAR‑T therapies for cancer, with lead programs in non‑Hodgkin lymphoma and small‑cell lung cancer.
• Industry classification: Pharmaceutical / Biotechnology.
• Consideration: Cash – EUR 48 million, payable in instalments as per the definitive agreement.
• Shareholding outcome: Mankind Netherlands will hold 70 % of ACTx; the remaining 30 % stays with existing shareholders.
• Regulatory approvals: Subject to any approvals required under the laws of the host country (Belgium/Netherlands).
• Completion timeline: To be determined as per the definitive agreement; no specific date disclosed.

---

Strategic Rationale

• Long‑term vision: Build a global, innovation‑led pharmaceutical business and expand Mankind’s pipeline beyond its traditional formulation and consumer‑health segments.
• Technology access: Entry into CAR‑T cell therapy, a high‑growth, high‑value therapeutic area with significant unmet medical need, especially in solid tumours and relapsed hematologic cancers.
• Geographic diversification: Strengthens Mankind’s presence in Europe and the United States through ACTx’s R&D teams located in the US and EU.

---

Regulatory & Compliance Highlights

• The disclosures satisfy Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements, together with the SEBI Master Circular No. HO/49/14/14(7)2025‑CFD‑POD2/I/3762/2026.
• The related‑party nature of the investment into Mankind Netherlands is exempt under the applicable SEBI provision.
• No change in the shareholding percentage of Mankind Pharma in its Dutch subsidiary; it remains a wholly‑owned entity.

---

Forward‑Looking Statements & Risk Factors

The press release contains forward‑looking statements regarding the anticipated benefits of the ACTx acquisition and the broader innovation strategy. Key risk factors highlighted include:

• Cash‑flow projections and currency fluctuations (EUR/INR).
• Industry and market conditions, including competition in CAR‑T space.
• Ability to obtain required regulatory approvals in multiple jurisdictions.
• Execution risk in managing rapid growth and integration of a biotech platform.
• Potential delays or failures in clinical development of ACTx’s pipeline.

Investors are advised to review the full safe‑harbour statement included in the announcement for a comprehensive list of risks.

---

Contact Information

Function	Contact Person	Email	Phone
Investor Relations	Prakash Agarwal	investor.relations@mankindpharma.com	+91‑11‑46846700
Corporate Communication	Natasha Raj	natasha.raj@mankindpharma.com	011‑46846700 Ext: 3201
PR Agency (Adfactors)	Smit Shah / Apoorva Sharma	smit.shah@adfactorspr.com / apoorva.sharma@adfactorspr.com	+91 9870789596 / +91 9999739452

---

The information above reflects the content of the Board meeting notice and accompanying press release dated 15 Oct 2026. No additional financial results or guidance were disclosed.